Clinical Trial Update: Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation [Phase 1, Phase 2]

View source ↗

Summary

Idera Pharmaceuticals reported results from a phase 1/2 dose-escalation trial in patients with relapsed or refractory diffuse large B-cell lymphoma bearing the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Idera investigational agent

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Diffuse Large B Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-11-14